Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...
Հիմնական հեղինակներ: | Sergey Shityakov, Ekaterina V. Skorb, Carola Y. Förster, Thomas Dandekar |
---|---|
Ձևաչափ: | Հոդված |
Լեզու: | English |
Հրապարակվել է: |
Frontiers Media S.A.
2021-10-01
|
Շարք: | Frontiers in Chemistry |
Խորագրեր: | |
Առցանց հասանելիություն: | https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full |
Նմանատիպ նյութեր
-
In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
: Ridwan Abiodun Salaam, և այլն
Հրապարակվել է: (2025-03-01) -
A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
: Madhura Punekar, և այլն
Հրապարակվել է: (2022-09-01) -
Editorial: Adopting drug repurposing to overcome drug resistance in cancer
: Eswar Shankar, և այլն
Հրապարակվել է: (2023-04-01) -
Network-based drug repurposing for potential stroke therapy
: Qihui Wu, և այլն
Հրապարակվել է: (2023-01-01) -
Approved drugs successfully repurposed against Leishmania based on machine learning predictions
: Rafeh Oualha, և այլն
Հրապարակվել է: (2024-09-01)